Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (4)

2022

  1. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

    Cancers, Vol. 14, Núm. 23

2019

  1. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Breast Cancer Research, Vol. 21, Núm. 1

  2. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

    Breast Journal, Vol. 25, Núm. 2, pp. 219-225

2018

  1. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii64